Clinical Trials Logo
  1. Home
  2. Chronic Pain
  3. NCT05976178
  4. Details
NCT05976178 Clinical Trial

Study of the Characteristics of Chronic Pain in Patients With Addiction

Chronic Pain Clinical Trial

— ADDICTALGO  

Official title:
Descriptive, Prospective Study of the Characteristics of Chronic Pain in Patients With Addiction to at Least One Substance

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05976178
Other study ID # 56LORC_2021_ADDICTALGO
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 10, 2022
Est. completion date October 10, 2024

Study information
Verified date August 2023
Source Groupe Hospitalier de Bretagne Sud
Contact Alexandre Cauchie, MD
Phone + 33 2 97 06 72 90
Email a.cauchie@ghbs.bzh
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It is described in the literature a higher prevalence of pain in patients with an addiction but there are few studies describing the pain profile of patients with use disorder. Pain has a very negative impact on the quality of life of opioid substituted patients. Improving knowledge on this point would make it possible to better guide specific care. The investigator proposes to conduct a single-center descriptive observational study using questionnaires, without changing the management of patients with chronic pain. The primary objective of the study is to determine the prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment.

Description:

It is described in the literature a higher prevalence of pain in patients with an addiction but there are few studies describing the pain profile of patients with use disorder. Pain has a very negative impact on the quality of life of opioid substituted patients. Improving knowledge on this point would make it possible to better guide specific care. The investigator proposes to conduct a single-center descriptive observational study using questionnaires, without changing the management of patients with chronic pain. All patients admitted to hospitalization in the addiction department of the LORIENT Hospital will be offered participation in the study. The primary objective of the study is to determine the prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment. The study will also evaluate the impact on daily activities of the presence of two chronic pathologies: chronic pain and addiction, describe the frequency of the two main psychiatric comorbidities of chronic pain: anxiety and depression, describe the different components of chronic pain in patients with substance addiction, and get information on analgesic medications.

Recruitment information / eligibility
Status Recruiting
Enrollment 300
Est. completion date October 10, 2024
Est. primary completion date June 10, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - > 18 years old - Presence of addiction to at least one substance, based on DSM-5 criteria - Hospitalized in the addiction service of LORIENT Hospital - Knowing how to read and write French - Not objecting to their participation in the study after informed information Exclusion Criteria: - Already included during a precedent hospitalization - Adults subject to legal protection or deprived of their liberty.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Groupe Hospitalier Bretagne Sud Lorient

Sponsors (1)
Lead Sponsor Collaborator
Groupe Hospitalier de Bretagne Sud

Country where clinical trial is conducted

France, 

References & Publications (5)

Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009. Epub 2005 Aug 10. — View Citation

Larson MJ, Paasche-Orlow M, Cheng DM, Lloyd-Travaglini C, Saitz R, Samet JH. Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. Addiction. 2007 May;102(5):752-60. doi: 10.1111/j.1360-0443.2007.01759.x. — View Citation

Lusted A, Roerecke M, Goldner E, Rehm J, Fischer B. Prevalence of pain among nonmedical prescription opioid users in substance use treatment populations: systematic review and meta-analyses. Pain Physician. 2013 Nov-Dec;16(6):E671-84. — View Citation

Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003 May 14;289(18):2370-8. doi: 10.1001/jama.289.18.2370. — View Citation

Voon P, Greer AM, Amlani A, Newman C, Burmeister C, Buxton JA. Pain as a risk factor for substance use: a qualitative study of people who use drugs in British Columbia, Canada. Harm Reduct J. 2018 Jul 5;15(1):35. doi: 10.1186/s12954-018-0241-y. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Prevalence of chronic pain in patients with substance addiction hospitalized for addiction treatment. Percentage of patients presenting with pain for more than three months among patients hospitalized in an addiction service for the management of an addiction During the hospitalization, maximum 1 month
Secondary Pain intensity in the last 24 hours Results of the Brief Pain Inventory : worst and least of pain in the last 24 hours During the hospitalization, maximum 1 month
Secondary Interference of pain on the quality of life Result of Brief pain inventory on general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life. On a scale from 0 (does not interfere) to 10 (completely interferes) During the hospitalization, maximum 1 month
Secondary Localisation of pain Drawing on a diagram of a human body During the hospitalization, maximum 1 month
Secondary Describe the frequency of the two main psychiatric comorbidities of chronic pain: anxiety Results of the anxiety scale of Hospital Anxiety and Depression scale. Positive if > 8. Minimum 0, maximum 21 During the hospitalization, maximum 1 month
Secondary Describe the frequency of the two main psychiatric comorbidities of chronic pain: depression Results of the depression scale of Hospital Anxiety and Depression scale. Positive if > 8. Minimum 0, maximum 21 During the hospitalization, maximum 1 month
Secondary Describe the prevalence of fibromyalgia among patients with substance addiction Results of the Fibromyalgia Rapid Screening Tool. Suspicion of fibromyalgia if >5 yes. Maximum 6 yes During the hospitalization, maximum 1 month
Secondary Information on analgesics medication Collection of current analgesic medication taken every day During the hospitalization, maximum 1 month
Secondary Describe the prevalence of neuropathic pain among patients with substance addiction Results of the DN3 (neuropathic pain 3). Suspicion of neuropathic pain when > 3/7 During the hospitalization, maximum 1 month
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain